GH Research PLC

NASDAQ

Market Cap.

873.98M

Avg. Volume

389.63K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about GH Research PLC

GH Research PLC News

GH Research PLC Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
ghres.com

About GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC Earnings & Revenue

GH Research PLC Financials

Table Compare

Compare GHRS metrics with:

   

Earnings & Growth

GHRS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

GHRS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

GHRS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

GHRS

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

GH Research PLC Income

GH Research PLC Balance Sheet

GH Research PLC Cash Flow

GH Research PLC Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioNeutral

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

GH Research PLC Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

GH Research PLC Executives

NameRole
Mr. Aaron Cameron M.B.A.Chief Operating Officer
Dr. Velichka Valcheva M.D.Chief Executive Officer
Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the Board
Mr. Magnus HalleCo-Founder & MD of Ireland
Ms. Julie Ryan F.C.A.Vice President of Finance
NameRoleGenderDate of BirthPay
Mr. Aaron Cameron M.B.A.Chief Operating OfficerMale1985

--

Dr. Velichka Valcheva M.D.Chief Executive Officer1975

--

Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the BoardMale1969

--

Mr. Magnus HalleCo-Founder & MD of IrelandMale1997

--

Ms. Julie Ryan F.C.A.Vice President of FinanceFemale1986

--

Discover More

Streamlined Academy

GH Research PLC

NASDAQ

Market Cap.

873.98M

Avg. Volume

389.63K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

GH Research PLC News

GH Research PLC Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

GH Research PLC Earnings & Revenue

GH Research PLC Income

GH Research PLC Balance Sheet

GH Research PLC Cash Flow

GH Research PLC Financials Over Time

GH Research PLC Executives

NameRole
Mr. Aaron Cameron M.B.A.Chief Operating Officer
Dr. Velichka Valcheva M.D.Chief Executive Officer
Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the Board
Mr. Magnus HalleCo-Founder & MD of Ireland
Ms. Julie Ryan F.C.A.Vice President of Finance
NameRoleGenderDate of BirthPay
Mr. Aaron Cameron M.B.A.Chief Operating OfficerMale1985

--

Dr. Velichka Valcheva M.D.Chief Executive Officer1975

--

Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the BoardMale1969

--

Mr. Magnus HalleCo-Founder & MD of IrelandMale1997

--

Ms. Julie Ryan F.C.A.Vice President of FinanceFemale1986

--

GH Research PLC Insider Trades

No data available

DateNameRoleTransactionTypeShares

No data available

Streamlined Academy

Website screenshot
HealthcareBiotechnology
ghres.com

About GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about GH Research PLC

GH Research PLC Financials

Table Compare

Compare GHRS metrics with:

   

Earnings & Growth

GHRS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

GHRS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

GHRS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

GHRS

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

GH Research PLC Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioNeutral

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)